These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 10376237)

  • 41. Long-term follow-up after a drug trial for panic disorder.
    Katschnig H; Amering M; Stolk JM; Klerman GL; Ballenger JC; Briggs A; Buller R; Cassano G; Garvey M; Roth M
    Br J Psychiatry; 1995 Oct; 167(4):487-94. PubMed ID: 8829718
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients.
    Tiffon L; Coplan JD; Papp LA; Gorman JM
    J Clin Psychiatry; 1994 Feb; 55(2):66-9. PubMed ID: 8077156
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine.
    Klein E; Colin V; Stolk J; Lenox RH
    Am J Psychiatry; 1994 Dec; 151(12):1760-6. PubMed ID: 7977882
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders.
    Pyke RE; Greenberg HS
    J Clin Psychopharmacol; 1989 Feb; 9(1):15-21. PubMed ID: 2651489
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Maintenance drug therapy of panic disorder.
    Curtis GC; Massana J; Udina C; Ayuso JL; Cassano GB; Perugi G
    J Psychiatr Res; 1993; 27 Suppl 1():127-42. PubMed ID: 8145175
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Subtyping panic disorder by major depression and avoidance behaviour and the response to active treatment.
    Maier W; Rosenberg R; Argyle N; Buller R; Roth M; Brandon S; Benkert O
    Eur Arch Psychiatry Clin Neurosci; 1991; 241(1):22-30. PubMed ID: 1832302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug treatment of panic disorder: early response to treatment as a predictor of final outcome.
    Albus M; Lecrubier Y; Maier W; Buller R; Rosenberg R; Hippius H
    Acta Psychiatr Scand; 1990 Nov; 82(5):359-65. PubMed ID: 2281806
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Service utilization and expenditures for the treatment of panic disorder.
    Leon AC; Olfson M; Portera L
    Gen Hosp Psychiatry; 1997 Mar; 19(2):82-8. PubMed ID: 9097062
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder.
    Lepola U; Arató M; Zhu Y; Austin C
    J Clin Psychiatry; 2003 Jun; 64(6):654-62. PubMed ID: 12823079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo.
    Marchand A; Coutu MF; Dupuis G; Fleet R; Borgeat F; Todorov C; Mainguy N
    Cogn Behav Ther; 2008; 37(3):146-59. PubMed ID: 18608313
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam.
    Kaplan GB; Greenblatt DJ; Ehrenberg BL; Goddard JE; Harmatz JS; Shader RI
    J Clin Psychopharmacol; 2000 Jun; 20(3):338-46. PubMed ID: 10831021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The efficacy of alprazolam in the therapy of panic disorders].
    Diukova GM; Vorob'eva OV; Petrova EP; Smirnov SV; Tumalaeva ZN
    Zh Nevrol Psikhiatr Im S S Korsakova; 1995; 95(4):9-13. PubMed ID: 8533521
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder.
    Lydiard RB; Lesser IM; Ballenger JC; Rubin RT; Laraia M; DuPont R
    J Clin Psychopharmacol; 1992 Apr; 12(2):96-103. PubMed ID: 1573046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of alprazolam, imipramine, and placebo in the treatment of depression.
    Feighner JP; Aden GC; Fabre LF; Rickels K; Smith WT
    JAMA; 1983 Jun; 249(22):3057-64. PubMed ID: 6133970
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Surreptitious drug use by patients in a panic disorder study.
    Clark DB; Taylor CB; Roth WT; Hayward C; Ehlers A; Margraf J; Agras WS
    Am J Psychiatry; 1990 Apr; 147(4):507-9. PubMed ID: 1969248
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.
    Mavissakalian MR; Perel JM
    Am J Psychiatry; 1995 May; 152(5):673-82. PubMed ID: 7726306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sertraline and alprazolam in the treatment of panic desorder.
    Fiseković S; Loga-Zec S
    Bosn J Basic Med Sci; 2005 May; 5(2):78-81. PubMed ID: 16053461
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A double-blind clinical trial of alprazolam, imipramine, or placebo in the depressed elderly.
    Weissman MM; Prusoff B; Sholomskas AJ; Greenwald S
    J Clin Psychopharmacol; 1992 Jun; 12(3):175-82. PubMed ID: 1629383
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study.
    Dunner DL; Ishiki D; Avery DH; Wilson LG; Hyde TS
    J Clin Psychiatry; 1986 Sep; 47(9):458-60. PubMed ID: 2875064
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.
    Lesser IM; Lydiard RB; Antal E; Rubin RT; Ballenger JC; DuPont R
    Am J Psychiatry; 1992 Nov; 149(11):1556-62. PubMed ID: 1415824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.